Watch how COSENTYX® is thought to help you move and feel better
Did you know an overactive immune system is like an overactive tennis ball machine? Watch this video to see how taking COSENTYX can help you get back into the swing of things.
What makes COSENTYX different?
COSENTYX specifically targets and blocks IL-17A, one of the multiple molecules that is believed to play a role in inflammation in people with non-radiographic axial spondyloarthritis.
Why is it important to target and block IL-17A?
Although some IL-17A is normal, when there’s an overproduction of IL-17A, your body becomes overwhelmed. This leads to damaging inflammation, causing you to see and feel symptoms like back pain, stiffness, and reduced mobility.
COSENTYX can help so you don’t have to fight as hard through your day
In a clinical trial, many people taking COSENTYX saw at least a 40% improvement in overall symptoms at 16 weeks,† with many continuing to see similar results at 1 year.‡
†41% of people taking COSENTYX vs 28% taking placebo.
‡38% of people taking COSENTYX vs 19% taking placebo.
COSENTYX has been extensively studied for 12 years across all indications. In January 2015, it was approved by the FDA to treat adults with moderate to severe plaque psoriasis. Later, in January 2016, COSENTYX was approved by the FDA to treat adults with active psoriatic arthritis and a form of axial spondyloarthritis (axSpA) called active ankylosing spondylitis. Most recently, in June 2020, it was approved by the FDA to treat adults with another form of axSpA: non-radiographic axial spondyloarthritis.